Personalized medicine has evolved so much over the past decade.
Join Dr. Rauh, an expert in cancer care to learn how biomarker testing is being used to determine the exact profile of a blood cancer, monitor its progression and determine the best treatment option available to someone who is newly diagnosed.
Michael Rauh, MSc, PhD, MD, FRCPC
Attending Hematopathologist, Kingston General Hospital
Associate Professor, Dept. Pathology & Molecular Medicine
Michael Rauh is Clinician-Scientist at Queen’s University and Kingston Health Sciences Centre, appointed in 2011. His combined MD and PhD training was conducted at the University of British Columbia and Terry Fox Lab of the BC Cancer Agency. Specialized Hematological Pathology training was conducted at the University of Toronto. His clinical practice and research focus is centered on myeloid blood cancers, particularly understanding their genetic and immune origins. The major focus of his research program is shifting to the common, age-related, pre-cancerous condition known as clonal hematopoiesis (CH or CHIP). Clonal hematopoiesis may serve as a biomarker for early cancer detection and, hopefully one day soon, a paradigm for the prevention of leukemia and lymphoma.